Evidence map›Paper›PMID 27165168›Full record

ArticleCancer causes & control : CCC2016

Antidepressant use and circulating prolactin levels.

Katherine W Reeves, Olivia I Okereke, Jing Qian, Shelley S Tworoger, Megan S Rice, Susan E Hankinson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. The Involvement of Prolactin in Stress-Related Disorders.International journal of environmental research and public health · 2023
    Review
  4. Mechanisms of Central Hypogonadism.International journal of molecular sciences · 2021
    Review
  5. Article
  6. Depression, Antidepressant Use, and Breast Cancer Risk in Pre- and Postmenopausal Women: A Prospective Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katherine W ReevesDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst, 411 Arnold House, 715 North Pleasant Street, Amherst, MA, 01003, USA. kwreeves@schoolph.umass.edu.
Olivia I OkerekeChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Jing QianDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst, 411 Arnold House, 715 North Pleasant Street, Amherst, MA, 01003, USA.
Shelley S TworogerChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Megan S RiceChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Susan E HankinsonDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst, 411 Arnold House, 715 North Pleasant Street, Amherst, MA, 01003, USA.

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, TAMIMI, RULLA M · 2000 to 2019
$77.8M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
Premonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
Psychological stress, associate biologic mediators, and ovarian cancer riskR01CA163451 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2012 to 2015
$1.7M
Depression, Antidepressant Use, and Breast Cancer RiskR03CA186228 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI REEVES, KATHERINE WHITNEY · 2014 to 2015
$177k
NCI NIH HHS P01 CA087969NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA163451NCI NIH HHS R03 CA186228NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA186107
6 · The paper itself

Abstract

purposeTo determine whether antidepressants (AD), specifically selective serotonin reuptake inhibitors (SSRIs), are linked to elevated prolactin levels among the general population.

methodsCirculating prolactin levels were available for 4593 healthy participants in the Nurses' Health Study (NHS) and NHS2, including 267 AD users. We fit generalized linear models to calculate and compare adjusted mean prolactin levels between AD users and non-users and further among SSRI users. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) for "elevated" prolactin levels (>11 ng/mL) comparing AD users to non-users. We evaluated AD use and change in prolactin levels among 610 NHS participants with two measurements an average of 11 years apart.

resultsAdjusted geometric mean prolactin levels were similar among SSRI users (13.2 ng/mL, 95 % CI 12.2-14.4), users of other classes of ADs (12.7 ng/mL, 95 % CI 11.0-14.6), and non-users (13.1 ng/mL, 95 % CI 12.8-13.4). Neither AD use (OR 1.17, 95 % CI 0.89-1.53) nor SSRI use (OR 0.95, 95 % CI 0.66-1.38) was associated with elevated prolactin levels. Change in prolactin levels was similar across women who started, stopped, consistently used, or never used ADs.

conclusionsThis study does not support the hypothesis that AD use would influence breast cancer risk via altered prolactin levels. These results provide some evidence that use of ADs to treat depression or other conditions may not substantially increase prolactin levels in the majority of women.

Indexed as

AdultAntidepressive AgentsDepressionFemaleHumansLogistic ModelsMiddle AgedProlactinSelective Serotonin Reuptake InhibitorsAntidepressive AgentsProlactinSelective Serotonin Reuptake InhibitorsAntidepressantsProlactinSelective serotonin reuptake inhibitorsWomen

Identifiers

PMID27165168
PMCPMC4925273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.